查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1981073

全球细胞株开发市场规模、份额、趋势和成长分析报告（2026-2034）

Global Cell Line Development Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

细胞株开发市场预计将从 2025 年的 89.5 亿美元成长到 2034 年的 223 亿美元，2026 年至 2034 年的复合年增长率为 10.67%。

受製药和生物技术产业对生物製药和生物相似药需求不断增长的推动，全球细胞株开发市场正经历显着成长。细胞株对于单株抗体、疫苗和重组蛋白的生产至关重要。慢性病盛行率的上升以及对先进治疗方案日益增长的需求，正促使製药公司投资于高效且扩充性的细胞株开发技术。

基因工程、细胞培养技术和自动化领域的科技进步是推动市场成长的关键因素。 CRISPR基因编辑、先进的表达系统和高通量筛检方法等工具正在提高细胞株开发的效率和准确性。此外，生物製药研发投入的不断增加也拓展了细胞株在药物发现和生产上的应用范围。

未来，随着个人化医疗和生物製药需求的成长，细胞株开发市场预计将稳定成长。各公司正致力于开发更稳定、高产量的细胞株，以提高生产效率。生物技术研究的拓展以及製药公司与研究机构合作的加强，将进一步巩固市场前景。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球细胞株开发市场：依产品与服务划分

  • 市场分析、洞察与预测
  • 试剂和培养基
  • 装置
  • 配件和耗材
  • 服务

第五章：全球细胞株开发市场：依原料划分

  • 市场分析、洞察与预测
  • 哺乳动物
  • 非哺乳动物

第六章 全球细胞株开发市场：依细胞株

  • 市场分析、洞察与预测
  • 重组
  • 融合瘤
  • 连续培养细胞株
  • 原代细胞株

第七章：全球细胞株开发市场：依应用划分

  • 市场分析、洞察与预测
  • 生物生产
  • 药物发现
  • 毒性测试
  • 组织工程
  • 研究

第八章：全球细胞株开发市场：依最终用途划分

  • 市场分析、洞察与预测
  • 製药和生物技术公司
  • 学术研究机构
  • 受託研究机构（CRO）

第九章 全球细胞株开发市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Advanced Instruments
    • Aragen Life Sciences
    • ASIMOV
    • Cytiva（Danaher Corporation）
    • Eurofins Scientific
    • Fyonibio
    • Genscript Biotech
    • Lonza Group
    • Novartis
    • ProBioGen
    • PromoCell
简介目录
Product Code: VMR11210338

The Cell Line Development Market size is expected to reach USD 22.30 Billion in 2034 from USD 8.95 Billion (2025) growing at a CAGR of 10.67% during 2026-2034.

The global cell line development market is experiencing significant growth due to the increasing demand for biologics and biosimilars in the pharmaceutical and biotechnology industries. Cell lines are essential for producing monoclonal antibodies, vaccines, and recombinant proteins. The rising prevalence of chronic diseases and the growing need for advanced therapeutic solutions are encouraging pharmaceutical companies to invest in efficient and scalable cell line development technologies.

Technological advancements in genetic engineering, cell culture techniques, and automation are key drivers supporting market growth. Tools such as CRISPR gene editing, advanced expression systems, and high-throughput screening methods are improving the efficiency and accuracy of cell line development. Additionally, increasing investments in biopharmaceutical research and development are expanding the application of cell lines in drug discovery and production.

In the future, the cell line development market is expected to grow steadily as demand for personalized medicine and biologic drugs increases. Companies are focusing on developing more stable, high-yield cell lines to improve production efficiency. The expansion of biotechnology research and growing collaboration between pharmaceutical firms and research institutions will further strengthen market prospects.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Products & Services

  • Reagents and Media
  • Equipment
  • Accessories and Consumables
  • Services

By Source

  • Mammalian
  • Non-mammalian

By Cell Line

  • Recombinant
  • Hybridomas
  • Continuous Cell Lines
  • Primary Cell Lines

By Application

  • Bioproduction
  • Drug Discovery
  • Toxicity Testing
  • Tissue Engineering
  • Research

By End Use

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations (CROs)

COMPANIES PROFILED

  • Advanced Instruments, Aragen Life Sciences, ASIMOV, Cytiva Danaher Corporation, Eurofins Scientific, Fyonibio, Genscript Biotech, Lonza Group, Novartis, ProBioGen, PromoCell
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL LINE DEVELOPMENT MARKET: BY PRODUCTS & SERVICES 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Products & Services
  • 4.2. Reagents and Media Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Equipment Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Accessories and Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL LINE DEVELOPMENT MARKET: BY SOURCE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Source
  • 5.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Non-mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL LINE DEVELOPMENT MARKET: BY CELL LINE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Cell Line
  • 6.2. Recombinant Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Hybridomas Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Continuous Cell Lines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Primary Cell Lines Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL LINE DEVELOPMENT MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Application
  • 7.2. Bioproduction Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Drug Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Toxicity Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Tissue Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CELL LINE DEVELOPMENT MARKET: BY END USE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End Use
  • 8.2. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Contract Research Organizations (CROs) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CELL LINE DEVELOPMENT MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Products & Services
    • 9.2.2 By Source
    • 9.2.3 By Cell Line
    • 9.2.4 By Application
    • 9.2.5 By End Use
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Products & Services
    • 9.3.2 By Source
    • 9.3.3 By Cell Line
    • 9.3.4 By Application
    • 9.3.5 By End Use
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Products & Services
    • 9.4.2 By Source
    • 9.4.3 By Cell Line
    • 9.4.4 By Application
    • 9.4.5 By End Use
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Products & Services
    • 9.5.2 By Source
    • 9.5.3 By Cell Line
    • 9.5.4 By Application
    • 9.5.5 By End Use
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Products & Services
    • 9.6.2 By Source
    • 9.6.3 By Cell Line
    • 9.6.4 By Application
    • 9.6.5 By End Use
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL CELL LINE DEVELOPMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Advanced Instruments
    • 11.2.2 Aragen Life Sciences
    • 11.2.3 ASIMOV
    • 11.2.4 Cytiva (Danaher Corporation)
    • 11.2.5 Eurofins Scientific
    • 11.2.6 Fyonibio
    • 11.2.7 Genscript Biotech
    • 11.2.8 Lonza Group
    • 11.2.9 Novartis
    • 11.2.10 ProBioGen
    • 11.2.11 PromoCell